NuCana PLC (NCNA) Stock Analysis
Verdict: AVOID
Terminal clinical-stage cash burn and 95% price collapse make this a binary 'zero or hero' bet with the odds heavily favoring zero.
Investment score: 18/100
Analysis as of
Is NuCana PLC stock worth reviewing? The TradeMates thesis
NCNA is a micro-cap biotech in a death spiral. Its technicals are broken, its earnings are non-existent, and its market valuation is currently lower than its reported cash, signaling extreme market distrust.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
NuCana PLC opportunities and risks
What speaks for NCNA
- Trading Below Cash Value
What speaks against NCNA
- Imminent Equity Dilution
Peers and competitors
- APTA.L
- SVNS.L
- CIZ.L
- GENF.L
- PBX.AQ
Frequently asked questions about NuCana PLC (NCNA)
Is NCNA stock a good investment?
The TradeMates model rates NuCana PLC as AVOID with an investment score of 18/100. NCNA is a micro-cap biotech in a death spiral. Its technicals are broken, its earnings are non-existent, and its market valuation is currently lower than its reported cash, signaling extreme market distrust. This is algorithmic model output, not personal investment advice.
Is NCNA stock a buy?
The TradeMates model verdict for NCNA is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.